Morepen Laboratories Shares Surge 191% in Four Months Amid FDA Filing

Morepen Laboratories witnessed a remarkable surge in its share price, reaching a fresh peak of ₹135.35 on the Bombay Stock Exchange (BSE) during intraday trading on Thursday. The stock climbed 7 percent, continuing the momentum from the previous day, even as the broader market showed weakness. Over the last two days, Morepen’s shares have advanced 14 percent, reflecting strong investor interest.

Looking at a longer time frame, Morepen Laboratories' stock has soared by 191 percent in just four months, up from ₹46.56. At 3:12 PM on Thursday, the stock was trading 6.4 percent higher at ₹134, contrasting with the BSE Sensex, which was down by 0.68 percent. The trading volume also saw a significant increase, with nearly 39 million shares exchanging hands across the National Stock Exchange (NSE) and BSE, more than doubling the average activity.

Key Catalyst: ANDA Submission to US FDA

The primary driver behind Morepen’s stock rally is the announcement made on September 29, 2026. The company disclosed that it has submitted its first Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration (FDA) for Sitagliptin tablets, available in 25 mg, 50 mg, and 100 mg dosages. This marks a strategic expansion for Morepen as it steps into integrated finished-dose development and regulatory submissions, broadening its scope beyond its existing active pharmaceutical ingredient (API) and contract development and manufacturing organisation (CDMO) operations.

The ANDA submission is significant because it extends Morepen’s capabilities to cover formulation development, bioequivalence testing, analytical validation, stability studies, and regulatory batch manufacturing. These advancements position the company to offer a more comprehensive suite of pharmaceutical development services.

Morepen has projected an approval timeline of 24 to 36 months after the submission, contingent on FDA review processes, facility inspections, and patent or exclusivity stipulations. The current patent for the US sitagliptin phosphate salt is set to expire in November 2026, with pediatric exclusivity lasting until May 2027. However, some manufacturers have arrangements that allow earlier market entry.

Strategic Growth and Market Positioning

This program enhances Morepen’s capacity to undertake specialized CDMO assignments, combining API development with finished-dose formulation and regulatory filings. The company plans to expand these capabilities through customer development projects, technology transfers, co-development agreements, and licensing deals.

Morepen Laboratories is transitioning from its traditional API manufacturing roots toward an innovation-driven manufacturing platform. Its focus includes securing long-term supply contracts, enhancing CDMO partnerships, scaling up processes, and catering to regulated-market clients with global pharmaceutical collaborations.

In addition to pharmaceutical manufacturing, Morepen is growing its Medical Devices segment. This division targets chronic care management with products like blood glucose monitors, blood pressure monitors, recurring consumables, continuous glucose monitoring (CGM) systems, and connected health devices.

Outlook and Industry Context

In its fiscal year 2026 annual report, Morepen outlined a positive medium-term outlook. The company benefits from a diversified portfolio spanning APIs, CDMO services, formulations, over-the-counter (OTC) products, and home healthcare. It boasts a strong product pipeline and an expanding global regulatory footprint, with a strategic emphasis on high-value and specialty products.

Morepen appears well-positioned to meet rising demand for complex APIs and specialty therapies. Its strengths include CRDMO/CDMO services and manufacturing APIs that substitute imports. The company is poised to leverage opportunities created by the global biologics patent expirations, supply chain diversification efforts, advancements in AI-driven drug discovery, and supportive government initiatives such as Atmanirbhar Bharat.

Overall, Morepen Laboratories’ recent FDA filing and robust stock performance highlight its evolving role in the pharmaceutical sector. As it broadens its capabilities and market reach, Morepen’s strategy aligns with broader industry trends toward integrated drug development, regulatory compliance, and diversified healthcare solutions.